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Abstract:  
Elevated blood pressure is the leading heritable risk factor for cardiovascular disease 
worldwide. We report genetic association of blood pressure (systolic, diastolic, pulse 
pressure) among UK Biobank participants of European ancestry with independent replication 
in other cohorts, and robust validation of 107 independent loci. We also identify new 
independent variants at 11 previously reported blood pressure loci. Combined with results 
from a range of in silico functional analyses and wet bench experiments, our findings highlight 
new biological pathways for blood pressure regulation enriched for genes expressed in 
vascular tissues and identify potential therapeutic targets for hypertension. Results from 
genetic risk score models raise the possibility of a precision medicine approach through early 
lifestyle intervention to offset the impact of blood pressure raising genetic variants on future 
cardiovascular disease risk.  
 
 
 
  
Elevated blood pressure (BP) is a strong, heritable1-4 and modifiable driver of risk for stroke 
and coronary artery disease and a leading cause of global mortality and morbidity5,6.  At the 
time of analysis, genome-wide association study (GWAS) meta-analyses, and analyses of 
bespoke or exome content, have identified and replicated genetic variants of mostly modest 
or weak effect on blood pressure at over 120 loci7-11. Here, we report association analyses 
between BP traits  and genetic variants among ~150,000 participants in UK Biobank,  a 
prospective cohort study of 500,000 men and women aged 40-69 years with extensive 
baseline phenotypic measurements, stored biological samples12, and follow-up by electronic 
health record linkage13. We undertake independent replication in large international 
consortia and other cohorts, providing robust validation of our findings and new biological 
insights into BP regulation. 
 
 
 
Our study design is summarized in Fig. 1. Briefly, data are available for 152,249 UK Biobank 
participants genotyped using a customised array (including GWAS and exome content) and 
with genome-wide imputation based on 1000 Genomes and UK10K sequencing data14. 
(Further details on the UK Biobank imputation are available at the UK Biobank website.) After 
quality measures and exclusions (see Online Methods), we study 140,886 unrelated 
individuals of European ancestry with two seated clinic BP measurements using the Omron 
HEM-7015IT device (Supplementary Table 1). We carry out GWAS analyses of systolic (SBP), 
diastolic (DBP) and pulse pressure (PP) using single-variant linear regression under an additive 
model, based on ~9.8 million single nucleotide variants (SNVs) with minor allele frequency 
(MAF) >1% and imputation quality score (INFO) >0.1. For SNVs with P <1x10-6, we take forward 
for replication the sentinel SNV (i.e. with lowest P-value) at each locus, defined by linkage 
disequilibrium (LD) r2 < 0.2, within a 1Mb interval. We similarly analyze exome content for 
variants with MAF >0.01%, including rare variants, taking into replication the sentinel SNV (P 
< 1x10-5) from loci that are non-overlapping (r2 <0.2) with the GWAS findings. Overall we took 
sentinel SNVs from 240 loci into replication: 218 from GWAS and 22 from exome analysis (r2 
< 0.2 and >500kb from previously reported BP SNVs at the time of analysis and not annotated 
to previously reported BP genes; Supplementary Table 2).  
 
The replication resources comprise individuals of European ancestry from a large BP meta-
analysis consortium (ICBP cohorts listed in Supplementary Note) and further cohorts with 
1000 Genomes data for GWAS (Supplementary Table 3), and two large BP exome consortia. 
We use P <5x10-8 to denote genome-wide significance in the combined (discovery and 
replication) meta-analyses, with P < 0.01 for support in the replication data alone and 
concordant direction of effect. Additionally, we take forward for replication potential 
secondary signals at 51 previously reported BP loci at the time of analysis (excluding the HLA 
region). 
To better understand the functional consequences of our findings, we carry out a series of in 
silico investigations and experimental analysis of gene expression in relevant vascular tissue 
for selected putative functional SNVs (Supplementary Fig. 1).   
RESULTS 
Genetic variants at novel and previously unvalidated loci 
Of the 240 loci taken forward to replication, we validate 107 loci at P < 5x10-8, of which 102 
derive from the GWAS analysis replicated and meta-analyzed in a total of 330,956 individuals 
(Tables 1-3; Supplementary Fig. 2a-c; Supplementary Fig. 3a), and a further five from the 
exome analysis in a total of 422,604 individuals (Tables 1-3 and Supplementary Fig. 3b; 
Supplementary Tables 4, 5 and 6). Thirty-two of these validated loci are novel findings. Since 
the time of analysis, the remaining 75 loci have also been reported in another study15, 
although at least 53 of these were previously unvalidated (Tables 1-3), hence we now validate 
these loci for the first time. We therefore present results here for all 107 validated loci in our 
study. Most SNVs also show association with hypertension in the UK Biobank data, for 
example 93 of the 107 validated sentinel SNVs are nominally significant (P < 0.01) 
(Supplementary Table 7). 
 
Of the 107 validated loci, 24 are reported for association with SBP as the primary trait (most 
significant from combined meta-analysis), 41 for DBP and 42 for PP, although many loci are 
associated with more than one BP trait (Supplementary Fig. 4). For example, in the combined 
meta-analysis, 24 validated loci are associated with both SBP and DBP, 11 with SBP and PP, 
one locus with DBP and PP and four loci (NADK-CPSF3L, GTF2B, METTL21A-AC079767.3 and 
PAX2) with all three traits at genome-wide significance (Fig. 2). 
 
After conditional analysis on the sentinel SNV we identify an independent validated secondary 
SNV at five of the 107 loci (Supplementary Table 8a; Supplementary Table 9). Compared with 
previously reported SNVs at the time of analysis, the contribution of our validated loci 
increases the percentage trait variance explained by ~1%, e.g. to 3.56% for SBP. 
 
We report signals at known hypertension drug targets, including the angiotensin converting 
enzyme (ACE) locus (rs4308, P = 6.8 x 10-14, ACE-inhibitors), CACNA2D2 (rs743757, P = 2.4 x 
10-10, calcium channel blockers), MME (rs143112823 in the RP11-439C8.2 locus, P = 1.4 x 10-
14, omapatrilat), ADRA2B (rs2579519 in the GPAT2-FAHD2CP locus, P = 4.8 x 10-12, beta 
blockers), SLC14A2 (rs7236548, P = 2.0 x 10-18, nifedipine), and phosphodiesterase 5A (PDE5A; 
rs66887589, P = 3.4 x 10-15, sildenafil).  
 
Additionally, we evaluate our validated SNVs, where available, in cohorts of non-European 
ancestry9-11, while recognizing that these analyses are likely underpowered (Supplementary 
Table 10). We find concordance in direction of effect (P <0.05) for GWAS SNVs for all three 
BP traits among individuals of East Asian ancestry and for DBP for South Asian ancestry, also 
for exome SNVs among individuals of Hispanic ancestry, pointing to cosmopolitan effects for 
many of the BP associated variants.  
 
A PhenoScanner16 search showed that 27 of our 107 validated sentinel SNVs (or proxies; r2 ≥ 
0.8) exhibit genome-wide significant associations with other traits (Supplementary Fig. 5), 
including coronary artery disease and myocardial infarction (where BP is likely on the causal 
pathway17), cardiovascular risk factors (e.g. lipids, height, body mass index) and non-
cardiovascular traits (e.g. lung function, cancer, Alzheimer’s). 
Variants at previously reported loci at time of analysis 
In conditional analyses, we identify 22 secondary SNVs (17 common, one rare, four low-
frequency variants) that are conditionally independent of the BP associated SNVs at 16 
previously reported loci at the time of analysis (Supplementary Table 8b; Supplementary 
Tables 11 and 12). One rare variant (rs138582164, MAF=0.1%) in the CDH17 locus anticipated 
to act as an exonic stop/gain mutation at the GEM gene is associated with a relatively large 
effect on PP (3.5 mm Hg per allele copy, Supplementary Table 8b). At three previously 
reported loci (EBF1, PDE3A, JAG1) we identify multiple independent secondary SNVs in 
addition to the previously reported SNVs (Supplementary Table 11).  
 
The UK Biobank data show support (P < 0.01) for 119 of 122 previously reported BP loci at the 
time of analysis (159 of 163 SNVs) for one or more BP traits (Supplementary Fig. 2 a-c; 
Supplementary Table 13). We do not show support for one SNV (rs11066280, RPL6-ALDH1) 
identified from a GWAS of East Asian ancestry18, which may indicate ancestry-specific effects. 
We compare the MAF and effect sizes in UK Biobank with published results of previously 
reported variants (Supplementary Fig. 6), indicating consistency of results between the two 
sources of data. 
We also examine findings for low-frequency and rare gene mutations previously reported to 
be associated with monogenic hypertension disorders19 and included on the UK Biobank gene 
array. Despite lack of power overall, the variant with the lowest P-value (rs387907156; KLH3; 
MAF=0.02%) has a seemingly large effect on BP: 8.2 mm Hg (SE=4.1, P = 0.046) per allele for 
SBP; 5.6 mm Hg (SE=2.6, P = 0.048) for PP (Supplementary Table 14). 
 
Functional analyses  
We annotate the 107 validated loci to 212 genes (based on LD r2 ≥0.8) and seek putative 
function from in silico analyses and gene expression experiments. Candidate genes with the 
strongest supporting evidence are indicated in the last column of Supplementary Table 4 with 
an indication of the supporting data source. All genome-wide significant variants in LD (r2>0.8) 
with the variants reported here, ranked by supporting evidence, are annotated in 
Supplementary Table 15. Of the 107 validated sentinel SNVs three are Indels; all other 
variants are single nucleotide polymorphisms (SNPs). We identify non-synonymous SNVs at 
13 of the 107 validated loci (Supplementary Table 16), three of which are predicted to be 
damaging (ANNOVAR) in TFAP2D (rs78648104), NOX4 (rs56061986) and CCDC141 
(rs17362588, reported to be associated with heart rate20) (Supplementary Fig. 5a). Beyond 
the coding regions we identify 29 SNVs in 3’UTRs which are predicted to significantly weaken 
or cause loss of miRNA regulation by altering the recognition motif in seven genes, and 
strengthen or create target sites for miRNA binding in 13 genes (based on miRNASNP db, 
Supplementary Table 16). 
From our expression Quantitative Trait locus (eQTL) analysis (GTEx), 59 of the 107 validated 
loci contain variants with eQTLs in at least one tissue (Supplementary Table 17); arterial tissue 
has the largest number of loci with eQTLs (Supplementary Fig. 7), with targeted in silico 
analysis showing six loci with eQTLs in arterial tissue (Supplementary Table 16). For example, 
the GTEx tibial artery eQTL in SF3A3 (rs4360494) shows strong in silico supporting evidence, 
including an arterial DNase I site within which the major C allele removes a predicted AP-2 
binding site (Supplementary Fig. 8). Hence we prioritized this gene for in vitro functional 
analysis (see below).  
By considering all loci reported here (our 107 validated loci, and previously reported loci at 
the time of analysis), our DEPICT analysis identifies enrichment of expression across 31 tissues 
and cells (Supplementary Fig. 9; Supplementary Table 18), with greatest enrichment in the 
arteries (P = 1.9 x 10-6, false discovery rate (FDR) < 1%). We use FORGE to investigate and 
identify significant (FDR, P <0.05) cell type specific enrichment within DNase I hypersensitive 
sites in a range of tissues including dermal and lung microvascular endothelial cell types, and 
cardiac fibroblasts (Supplementary Fig. 10). For a set of curated candidate regulatory SNVs 
from our 107 validated loci (see Supplementary Note), widespread enrichment is found in 
microvascular endothelium, aortic smooth muscle, aortic fibroblasts, vascular epithelium, 
heart and skin (Supplementary Fig. 10). In addition, we identify significant enrichment of 
histone marks in a wide range of cell types, including strong enrichment seen for H3K4Me3 
(an activating modification found near promoters) marks in umbilical vein endothelial cells 
(HUVEC) (Supplementary Fig. 11). To explore expression at the level of cardiovascular cell 
types specifically, we use Fantom5 reference transcript expression data (see Online Methods) 
to cluster the 212 genes annotated to our 107 validated loci according to tissue specificity 
(Supplementary Fig. 12), with the significantly clustered genes forming four tissue-specific 
clusters, including a vascular smooth muscle cell (VSMC) and fibroblast cluster, an endothelial 
cell cluster (including probable endothelial cells in highly vascularized tissues), and a 
combined vascular cell cluster.    
Additionally, Ingenuity pathway analysis and upstream transcriptional analysis show 
enrichment of canonical pathways implicated in cardiovascular disease, including those 
targeted by antihypertensive drugs, such as the alpha-adrenergic, CXCR4, endothelin 
signalling and angiotensin receptor pathways (Supplementary Table 19). In keeping with 
vascular mediation of genetic influence we identify diphenyleneiodonium, an inhibitor of 
flavin-containing oxidases, including NAD(P)H oxidase (NOX), which is reported to reverse 
endothelial dysfunction (and hypertension) in a rat model21.  
To identify long range target genes of non-coding variants, we use chromatin interaction (Hi-
C) data from HUVEC, as enhancers and silencers often form chromatin loops with their target 
promoter. In most loci the strongest promoter interaction involves a gene in high LD with the 
SNV, but for 21 loci we find a distal potential target gene (Supplementary Table 16). Pathway 
analysis of the distal genes shows greatest enrichment in regulators of cardiac hypertrophy. 
We evaluate pleiotropy using the Genomic Regions Enrichment of Annotations Tool (GREAT) 
to study enrichment of mouse phenotype and human disease ontology terms across all loci 
reported here. These highlight cardiovascular system abnormalities and vascular disease as 
the most highly enriched terms (Supplementary Fig. 5b & 5c).  
Collectively evidence from eQTLs, DEPICT, DNase I sites, histone marks, Hi-C data and 
ontological analyses indicates predominant vascular and cardiovascular tissue involvement 
for genes within the BP associated loci. 
We also look for association of our validated sentinel SNVs with metabolomic signatures. 
Three SNVs within the NOX4, KCNH4 and LHFPL2 loci show significant associations (family-
wise error rate < 5%) with lipoprotein sub-fractions from 1H Nuclear Magnetic Resonance 
(NMR) spectroscopy analysis of 2,000 Airwave study samples (Supplementary Tables 20 and 
21). The results for these variants suggest a link between BP regulation and lipid metabolism. 
Eleven SNVs (including at LHFPL2 locus) show association (family wise error rate < 5%) with 
metabolites in blood or urine from the publicly available “Metabolomics GWAS Server” 
resource based on mass spectrometry22,23 (Supplementary Table 21), including sugar acids, 
sphingolipids, fatty acids, glycerophospholipids, organic acids and benzene derivatives.   
Several genes and variants with putative function are highlighted in our in silico analysis as 
having biological support (e.g. eQTLs or nsSNVs) and those with novelty and tractability to 
laboratory investigation (e.g. expression in available tissue models) are prioritized. Sentinel 
variants in three genes which were highly significant in the combined meta-analysis (Tables 2 
and 3) are selected for experimental testing and were successfully genotyped, each for at 
least 100 samples. We select ADAMTS7 due to strong biological support (e.g. mouse knockout 
phenotype), SF3A3 due to eQTLs, and NOX4 as it contains a rare nsSNV (Supplementary Table 
9) in addition to common variant associations. We use quantitative polymerase chain reaction 
(qPCR) to study the impact of these sentinel variants on gene expression in human VSMCs 
and endothelial cells (ECs) (see Online Methods). For SF3A3, the major C allele of variant 
rs4360494 associated with increased PP (0.278 mmHg ±0.03, P=3.7x10-16, N=307,682) is 
associated with SF3A3 expression in human VSMCs, although not in endothelial cells 
(Supplementary Fig. 13a); and the T allele of SNV rs62012628 in ADAMTS7 associated with 
lower DBP (0.238 mmHg ±0.03, P=5.1x10-12, N=244,143), is associated with reduced 
ADAMTS7 expression in human VSMCs (Supplementary Fig. 13b), while the minor A allele of 
SNV rs2289125 at the NOX4 locus associated with lower PP (-0.377 mmHg ±0.04, P=9.1x10-22, 
N=282,851) correlates with increased NOX4 expression in ECs though not VSMCs 
(Supplementary Fig. 13c). Our study thus finds evidence for novel cis-eQTLs in ADAMTS7 and 
NOX4 in addition to validating the previously reported GTEx eQTL in SF3A3, and supports the 
vascular expression of these genes.   
Genetic risk score analyses 
We create an unbiased genetic risk score (GRS) (Supplementary Table 22) to evaluate, in an 
independent cohort (Airwave, see Online Methods), the impact of the combination of all loci 
reported here on BP levels and risk of hypertension. When compared with the lowest quintile 
of the distribution of the GRS, individuals >50 years in the highest quintile have sex-adjusted 
mean SBP higher by 9.3 mm Hg (95% CI 6.9 to 11.7 mm Hg, P =1.0 x 10-13) and an over two-
fold higher risk of hypertension (OR 2.32 95% CI 1.76 to 3.06; P=2.8 x 10-9) compared with 
individuals in the lowest quintile (Fig. 3; Supplementary Table 23). Similar results were 
obtained from GRS associations with BP and hypertension within UK Biobank (Supplementary 
Table 24). In UK Biobank − based on self-reported health data, record linkage to Hospital 
Episode Statistics and mortality follow-up data (Supplementary Table 25) − we show that the 
GRS is associated with increased risk of stroke, coronary heart disease and all cardiovascular 
outcomes; comparing the upper and lower fifths of the GRS distribution, sex-adjusted odds 
ratios are 1.34 (95% CI 1.20 to 1.49, P =1.5×10-7), 1.38 (95% CI 1.30 to 1.47, P= 4.3×10-23) and 
1.35 (95% CI 1.27 to 1.42, P=1.3×10-25) respectively (Fig. 3; Supplementary Table 26). Results 
are also provided for incident-only cases (Supplementary Table 27). 
 
DISCUSSION  
A key attribute of this study is the combination of a large, single discovery sample with 
standardized BP measurement and dense 1000 Genomes/UK10K imputation, yielding a high 
quality dataset with ~9.8 million variants14, taking advantage of major international consortia 
for parallel replication of common and low-frequency variants. In total we include GWAS data 
from 330,956 individuals and exonic SNVs from a total of 422,604 individuals. This strategy 
resulted in 107 robustly validated loci for BP traits, including 32 loci that have not previously 
been reported, and at least 53 further loci validated for the first time. Despite its size, our 
study is still under-powered to find low-frequency variants. Our findings are mostly common 
variants, with similarly modest effect sizes as variants previously reported at the time of 
analysis (Supplementary Fig. 14). The lack of rare variant discovery could also be due to the 
challenge of detecting rare variants from imputed data. There may be greater potential for 
identifying rare variants from the future release of genetic data for all 500,000 UK Biobank 
participants.  
Our findings point to new biology as well as highlighting gene regions in systems that have 
previously been implicated in the genetics of BP. Several of our validated loci affect 
atherosclerosis or vascular remodelling (ADAMTS7, THBS2, CFDP1) and exhibit locus 
pleiotropy in prior genome-wide association studies for coronary artery disease or carotid 
intimal-media thickness24-26 (Supplementary Fig. 5a  and Fig. 4). In previous work we have 
shown that expression of ADAMTS7 is upregulated and increases vascular smooth muscle cell 
migration in response to vascular injury in relation to a distinct coronary artery variant 
(rs3825807, not in LD with our sentinel SNV; r2 = 0.17)27. In endothelial cells ADAMTS7 
encodes a metalloproteinase to cleave thrombospondin-1 encoded by THBS2 which leads to 
reduced endothelial cell migration and plays a role in neo-intimal repair in the vessel wall27. 
Our functional work indicates that the allele associated with lower DBP is also associated with 
lower ADAMTS7 expression in human VSMCs; this fits with the murine knockout that exhibits 
reduced atherosclerosis. SF3A3 encodes a splicing factor with no prior links to BP other than 
our reported association and eQTL. At the CFDP1 locus our sentinel SNV is in high LD (r2 = 
0.95) with a variant previously associated with carotid intimal-medial thickness. Collectively 
our findings highlight a potential common mechanism among these genes in vascular 
remodelling that has previously been observed in small resistance arteries in essential 
hypertension28.  
NADPH oxidase 4 (NOX4) has an established role in the endothelium where it enhances 
vasodilatation and reduces blood pressure in vivo29. This oxidase generates reactive oxygen 
species in the endothelium and may contribute to salt sensitive hypertension in the kidney 
and the vasculature30-32. We found that the allele of the common variant at the NOX4 locus 
correlates with increased tissue specific NOX4 expression in endothelial cells rather than 
VSMCs (Supplementary Fig. 13c). NOX4 mediates endothelial cell apoptosis and facilitates 
vascular collagen synthesis contributing to endothelial dysfunction and arterial stiffness, and 
may explain the association with PP33,34.  
We identify several loci containing genes involved in vascular signalling and second 
messenger systems such as PDE5A and PDE10A35-37. The phosphodiesterase PDE5A 
hydrolyzes cyclic GMP and is inhibited by sildenafil which leads to vasodilatation38. This 
finding fits with our previous discoveries of a role for gene loci encoding elements of 
natriuretic peptide-nitric oxide pathway and guanylate cyclase signalling systems in BP 
regulation18,39,40.  Our findings strengthen the case for evaluating the opportunity to 
repurpose PDE5A inhibitors for use in hypertension. 
The importance of microvascular function is emphasised by the solute carrier transporters 
such as SLC14A2 encoding a urea transporter, which has previously been linked to autosomal 
dominant Streeten type orthostatic hypotensive disorder41 and BP response to nifedipine, a 
calcium channel blocker antihypertensive drug42.  SLC8A1 encodes a sodium calcium 
exchanger expressed in cardiomyocytes which alters cardiac contractility and hypertrophy 
and shows abnormal BP in SLC8A1 transgenic mice43. Variants at SLC35F1 have previously 
been associated with resting heart rate and ventricular size which could contribute to BP 
elevation44.  
We also identify loci that are involved in cardiovascular development (GATA2, KIAA1462, 
FBN2, FN1 and HAND2) such as fibrillin 2 (FBN2) which overlaps in action with fibrillin 1 in 
development of the aortic matrix45-49. In addition, fibronectin expression is increased in 
hypertension and in atherosclerosis but it may also play a role in the development of the 
heart49-51. 
Our analysis validates loci containing genes with prior physiological connection to BP such as 
BDNF, FAM208A, and CACNA2D252-54. The neurotrophin Brain Derived Neurotrophic Factor 
(BDNF) modulates angiotensin 11 in the brain to elevate BP in experimental models; higher 
serum levels correlate with reduced risk of cardiovascular disease and mortality52. In 
experimental models FAM208A, which is thought to be a transcription factor, is a strong 
candidate for a QTL for BP54. The gene CACNA2D2 encodes a subunit of the L-type calcium 
channel that is most abundantly expressed in the atrium and in neurones and may be a target 
for negatively chronotropic and inotropic calcium channel antagonists which reduce BP55.  
We examine long range genomic interactions using Hi-C, whereby the promoter region has a 
strong chromatin interaction with a novel SNV. One example is EPAS1, which is ~200kb away 
from the SNV (rs11690961). It encodes hypoxia-inducible factor 2alpha, which affects 
catecholamine homeostasis, protects against heart failure and mutations in the gene are 
associated with pulmonary hypertension56. Another such gene is INHBA, 1.3Mb away from 
the SNV (rs12531683), which is elevated in pulmonary hypertension and contributes to 
vascular remodelling by inducing expression of endothelin-1 and plasminogen activator 
inhibitor-1 in pulmonary smooth muscle cells57. 
Our observation of 9-10 mm Hg higher BP at age 50+ years when comparing the top vs bottom 
fifths of the BP GRS distribution has potential clinical and public health implications. We 
stratified by age due to a significant interaction of the GRS with age (P ranging between 
9.96×10-11 and 1.16×10-3 for interaction with continuous BP traits, P = 0.012 for hypertension). 
Measuring the GRS in early life raises the possibility of adopting an early precision medicine 
approach to offset the genetic risk through lifestyle intervention (i.e. reduced sodium intake, 
increased potassium intake, maintenance of optimal weight, low adult alcohol consumption 
and regular exercise)58-60. Studies of non-pharmacologic approaches to BP control indicate 
that 10 mm Hg or more reduction in SBP is an achievable goal through lifestyle measures 
alone61, while recent evidence suggests that favorable lifestyle may offset the cardiovascular 
sequelae associated with high genetic risk62. As the above data are observational, the extent 
to which adherence to lifestyle recommendations amongst high genetic risk individuals might 
result in favorable outcomes remains uncertain; given the substantial effect of GRS on BP by 
middle-age, the potential for adopting early lifestyle intervention amongst individuals at high 
genetic risk, along with population-wide measures to lower BP, warrants further study. 
Since the completion of our study, another BP GWAS using UK Biobank data has been 
published15, as part of a larger single-stage combined meta-analysis without replication; it 
reported a total of 316 loci, including 241 loci identified from the meta-analysis involving UK 
Biobank that were not tested for validation. Of the 107 validated loci reported in our study, 
32 are discovered and validated for the first time in our analysis of UK Biobank. In addition, 
75 sentinel SNVs are in LD (r2 ≥ 0.2) with the recently reported loci15 and we validate at least 
53 of these for the first time in our study (indicated by “GIU” in Tables 1-3). Furthermore we 
note that 49 of the reported loci from the recent study15 did not validate in our large 
independent replication resource. 
In summary we describe 107 validated loci for BP offering new biology, identifying potential 
new therapeutic targets and raising the possibility of a precision medicine approach to modify 
risk of hypertension and cardiovascular outcomes.  Altogether, this represents a major 
advance in our understanding of the genetic architecture of BP.  
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Figure 1: Study design schematic for discovery and validation of loci. N: sample size; QC: 1 
Quality Control; PCA: Principal Component Analysis; BP: blood pressure; SBP: systolic BP; DBP: 2 
diastolic BP; PP: pulse pressure; SNVs: single nucleotide variants; BMI: body mass index; UKB: 3 
UK Biobank; UKBL: UK BiLEVE; GWAS: Genome-wide association study; MAF: Minor Allele 4 
Frequency; P: P-value; LD: Linkage Disequilibrium; 1000G: 1000 Genomes. UKBBvsUKBL: a 5 
binary indicator variable for UK Biobank vs UK BiLEVE to adjust for the different genotyping 6 
chips 7 
 8 
Figure 2: Venn diagram of 107 validated loci from our study. This shows concordance of 9 
significant associations across the three blood pressure phenotypes for the 107 validated 10 
sentinel variants (Tables 1-3) from both the GWAS and exome analyses, according to 11 
genome-wide significance in the combined meta-analysis. The locus names labelled within 12 
the Venn Diagram correspond to Tables 1-3, and relate to the nearest annotated gene. The 13 
loci names in bold font highlight the 32 novel loci which are reported for the first time in our 14 
study. 15 
 16 
Figure 3: Distribution of Genetic Risk Score (GRS) and its relationship with blood pressure, 17 
hypertension and CVD outcomes. The GRS is based on all reported loci: both previously 18 
reported loci at the time of analysis; and all validated blood pressure variants from this 19 
study. (a) Distribution of GRS in Airwave and sex-adjusted odds ratio of hypertension in age 20 
50+ comparing each of the upper four GRS quintiles with the lowest quintile; dotted lines 21 
represent the upper 95% confidence intervals. (b) Mean blood pressures and standard 22 
deviation in bracket in Airwave age 50+ across GRS quintiles. (c) Distribution of GRS in UKB 23 
and sex-adjusted odds ratio of CVD, CAD and stroke comparing each of the upper four GRS 24 
quintiles with the lowest quintile; dotted lines represent the upper 95% confidence 25 
intervals. (d) Count of CVD, CAD and stroke (events and deaths) across GRS quintiles in UKB 26 
participants 27 
Figure 4: Summary of gene cardiovascular expression from validated loci. Genes are shown 28 
on the basis of their tissue expression and supporting evidence summarised in 29 
Supplementary Table 16, based on Knockout (KO) phenotype, previously reported blood 30 
pressure biology or a strong functional rationale: eQTL (expression Quantitative Trait Loci), 31 
nsSNV (non-synonymous SNV), Hi-C. Multiple lines of evidence indicate the central 32 
importance of the vasculature in blood pressure regulation and we thus highlight existing 33 
drugged (*) and druggable (#) targets among these genes.  Illustrations used elements with 34 
permission from Servier Medical Art. We note that some druggable genes may carry a safety 35 
liability, such as GJA1, which has known association with QT interval20 36 
  37 
Table 1: Loci validated with SBP as primary trait: combined meta-analysis results from (a) 38 
GWAS and (b) Exome for the sentinel variant 39 
(a) GWAS 
Locus Chr Pos rsID EA EAF N Beta SE P Note 
NADK-CPSF3L 1 1,685,921 rs139385870 D 0.5 281,890 -0.352 0.05 1.3x10-12 GIU 
CELA2A 1 15,798,197 rs3820068 A 0.81 310,776 0.425 0.06 1.1x10-12 GIU 
GTF2B 1 89,360,158 rs10922502 A 0.62 323,666 -0.382 0.05 2.2x10-15 GIU 
FOSL2 2 28,635,740 rs7562 T 0.52 319,942 0.263 0.05 1.9x10-8 
 
PRKD3 2 37,517,566 rs13420463 A 0.77 330,307 0.356 0.05 7.0x10-11 GIU 
METTL21A-AC079767.3 2 208,526,140 rs55780018 T 0.54 304,567 -0.391 0.05 5.9x10-16 GIU 
RYK 3 134,000,025 rs9859176 T 0.4 322,428 0.322 0.05 1.3x10-11 G 
NPNT 4 106,911,742 rs13112725 C 0.76 306,370 0.435 0.06 1.5x10-14 GIU 
TMEM161B 5 87,514,515 rs10059921 T 0.08 298,543 -0.526 0.09 4.0x10-9 GIU 
FBN2 5 127,868,199 rs6595838 A 0.3 328,401 0.344 0.05 7.6x10-12 GIU 
CASC15 6 22,130,601 rs6911827 T 0.45 326,471 0.296 0.05 2.0x10-10 GIU 
TFAP2D 6 50,683,009 rs78648104 T 0.92 305,426 -0.481 0.08 1.3x10-8 
 
MKLN1 7 131,059,056 rs13238550 A 0.4 325,647 0.331 0.05 1.9x10-12 
 
HIPK2 7 139,463,264 rs1011018 A 0.2 325,110 -0.329 0.06 1.5x10-8 
 
ZFAT 8 135,612,745 rs894344 A 0.6 329,834 -0.258 0.05 3.2x10-8 
 
PAX2 10 102,604,514 rs112184198 A 0.1 323,791 -0.659 0.08 3.6x10-18 GIU 
MCF2L 13 113,636,156 rs9549328 T 0.23 313,787 0.318 0.06 1.5x10-8 GI 
FERMT2 14 53,377,540 rs9888615 T 0.29 326,235 -0.318 0.05 3.5x10-10 GIU 
PPP2R5E 14 63,928,546 rs8016306 A 0.8 329,869 0.335 0.06 3.7x10-9 
 
ABHD17C 15 81,013,037 rs35199222 A 0.45 323,407 0.322 0.05 5.2x10-12 GI 
CFDP1 16 75,331,044 rs11643209 T 0.42 309,242 -0.339 0.05 1.8x10-12 GI 
CRK 17 1,333,598 rs12941318 T 0.49 299,739 -0.269 0.05 2.5x10-8 GIU 
ACOX1 17 73,949,045 rs2467099 T 0.22 326,401 -0.307 0.06 3.3x10-8 GIU 
(b) Exome 
SSPN 12 26,438,189 rs6487543 A 0.77 244,842 0.3 0.05 6.3x10-10 
 
Locus: named according to nearest annotated gene(s); Chr: chromosome; Pos: build 37; EA: effect 40 
allele; EAF: EA frequency in UK Biobank; Beta: effect estimate; SE: Standard Error of effect; P: P-41 
value; N: total sample size analyzed; Note: indicates loci published since our analysis15 from GERA 42 
(G), GERA+ICBP(HapMap) (GI) or GERA+ICBP(HapMap)+UKB (GIU) analyses. 43 
  44 
Table 2: Loci validated with DBP as primary trait: combined meta-analysis results from (a) 45 
GWAS and (b) Exome for the sentinel variant 46 
(a) GWAS 
Locus Chr Pos rsID EA EAF N Beta SE P Note 
chr1mb25 1 25,030,470 rs6686889 T 0.25 322,575 0.185 0.03 3.6x10-9   
DNM3 1 172,357,441 rs12405515 T 0.56 328,543 -0.165 0.03 1.4x10-9 GIU 
GPATCH2 1 217,718,789 rs12408022 T 0.26 320,983 0.198 0.03 2.4x10-10 GIU 
CDC42BPA 1 227,252,626 rs10916082 A 0.73 327,636 -0.177 0.03 8.4x10-9   
WNT3A 1 228,191,075 rs2760061 A 0.47 312,761 0.23 0.03 2.1x10-16 GIU 
SDCCAG8 1 243,471,192 rs953492 A 0.46 325,253 0.22 0.03 7.4x10-16 G 
ADCY3 2 25,139,596 rs55701159 T 0.89 321,052 0.285 0.04 7.2x10-11   
SLC8A1 2 40,567,743 rs4952611 T 0.58 309,395 -0.157 0.03 4.0x10-8   
AC016735.1 2 43,167,878 rs76326501 A 0.91 318,127 0.419 0.05 3.6x10-18   
GPAT2-FAHD2CP 2 96,675,166 rs2579519 T 0.63 311,557 -0.197 0.03 4.8x10-12   
TEX41 2 145,646,072 rs1438896 T 0.3 329,278 0.234 0.03 2.0x10-15 GIU 
CCDC141 2 179,786,068 rs79146658 T 0.91 321,318 -0.311 0.05 2.4x10-10 G 
TMEM194B 2 191,439,591 rs7592578 T 0.19 304,672 -0.24 0.04 9.5x10-12   
TNS1 2 218,668,732 rs1063281 T 0.6 315,354 -0.2 0.03 1.3x10-12 GIU 
CAMKV-ACTBP13 3 49,913,705 rs36022378 T 0.8 319,983 -0.202 0.03 4.7x10-9 GIU 
CACNA2D2 3 50,476,378 rs743757 C 0.14 328,836 0.245 0.04 2.4x10-10 GIU 
FAM208A 3 56,726,646 rs9827472 T 0.37 323,058 -0.177 0.03 4.3x10-10 GIU 
RP11-439C8.2 3 154,707,967 rs143112823 A 0.09 297,343 -0.403 0.05 1.4x10-14 GIU 
SENP2 3 185,317,674 rs12374077 C 0.35 327,513 0.163 0.03 9.2x10-9 GIU 
PDE5A 4 120,509,279 rs66887589 T 0.52 324,397 -0.215 0.03 3.4x10-15 GIU 
POC5 5 75,038,431 rs10078021 T 0.63 314,172 -0.164 0.03 1.3x10-8 G 
CPEB4 5 173,377,636 rs72812846 A 0.28 312,601 -0.209 0.03 2.2x10-11 GIU 
PKHD1 6 51,832,494 rs13205180 T 0.49 325,419 0.168 0.03 7.0x10-10 GIU 
PDE10A 6 166,178,451 rs147212971 T 0.06 296,010 -0.36 0.06 1.6x10-9 GIU 
SLC35F1 6 118,572,486 rs9372498 A 0.08 330,625 0.334 0.05 1.8x10-11 GIU 
SNX31 8 101,676,675 rs2978098 A 0.54 324,424 0.165 0.03 1.5x10-9   
RP11-273G15.2 8 144,060,955 rs62524579 A 0.53 268,645 -0.175 0.03 3.8x10-9 GIU 
MTAP 9 21,801,530 rs4364717 A 0.55 327,173 -0.175 0.03 1.3x10-10   
BDNF 11 27,728,102 rs11030119 A 0.31 330,002 -0.163 0.03 2.9x10-8 GIU 
MYEOV 11 69,079,707 rs67330701 T 0.09 276,760 -0.367 0.05 2.1x10-12 GIU 
RP11-321F6.1 15 66,869,072 rs7178615 A 0.37 318,076 -0.179 0.03 2.6x10-10   
ADAMTS7 15 79,070,000 rs62012628 T 0.29 244,143 -0.238 0.03 5.1x10-12   
chr15mb95 15 95,312,071 rs12906962 T 0.68 319,952 -0.221 0.03 5.6x10-14 GIU 
PPL 16 4,943,019 rs12921187 T 0.43 326,469 -0.174 0.03 2.5x10-10 G 
FBXL19 16 30,936,743 rs72799341 A 0.24 324,502 0.185 0.03 5.8x10-9 GIU 
CMIP 16 81,574,197 rs8059962 T 0.42 319,839 -0.17 0.03 1.3x10-9   
ACE 17 61,559,625 rs4308 A 0.37 319,394 0.213 0.03 6.8x10-14 GIU 
MAPK4 18 48,142,854 rs745821 T 0.76 330,954 0.189 0.03 1.4x10-9   
CCNE1 19 30,294,991 rs62104477 T 0.33 320,347 0.177 0.03 1.2x10-9 GIU 
PLCB1 20 8,626,271 rs6108168 A 0.25 327,368 -0.211 0.03 1.1x10-11   
(b) Exome 
MRAS 3 138,119,952 rs2306374 T 0.84 281,715 -0.184 0.03 7.4x10-9 GIU 
Locus: named according to nearest annotated gene(s); Chr: chromosome; Pos: build 37; EA: effect 47 
allele; EAF: EA frequency in UK Biobank; Beta: effect estimate; SE: Standard Error of effect; P: P-48 
value; N: total sample size analyzed; Note: indicates loci published since our analysis15 from GERA 49 
(G), GERA+ICBP(HapMap) (GI) or GERA+ICBP(HapMap)+UKB (GIU) analyses. 50 
  51 
Table 3: Loci validated with PP as primary trait: combined meta-analysis results from (a) 52 
GWAS and (b) Exome for the sentinel variant 53 
(a) GWAS 
Locus Chr Pos rsID EA EAF N Beta SE P Note 
chr1mb9 1 9,441,949 rs9662255 A 0.43 310,618 -0.207 0.03 1.9x10-10 GIU 
SF3A3 1 38,455,891 rs4360494 C 0.55 282,851 0.278 0.03 3.7x10-16 G 
RP4-710M16.1-PPAP2B 1 56,576,924 rs112557609 A 0.35 325,952 0.227 0.03 6.8x10-12 
 
FGGY 1 59,653,742 rs3889199 A 0.71 329,486 0.351 0.03 1.8x10-24 G 
C2orf43 2 20,881,840 rs2289081 C 0.36 329,140 -0.223 0.03 5.5x10-12 GI 
PRKCE 2 46,363,336 rs11690961 A 0.88 327,847 0.34 0.05 3.9x10-12 GIU 
CEP68 2 65,283,972 rs74181299 T 0.62 324,224 0.23 0.03 9.6x10-13 GIU 
TCF7L1 2 85,491,365 rs11689667 T 0.54 330,634 0.176 0.03 1.7x10-8 GIU 
FN1 2 216,300,482 rs1250259 A 0.74 325,485 -0.314 0.04 8.7x10-19 G 
GATA2 3 128,201,889 rs62270945 T 0.03 279,925 0.607 0.1 1.8x10-9 GIU 
PALLD 4 169,717,148 rs1566497 A 0.42 320,948 0.236 0.03 1.9x10-13 GI 
chr4mb174 4 174,584,663 rs17059668 C 0.92 313,277 -0.332 0.06 2.8x10-8 
 
LHFPL2 5 77,837,789 rs10057188 A 0.46 325,985 -0.205 0.03 6.7x10-11 GIU 
GJA1 6 121,781,390 rs11154027 T 0.47 316,708 0.207 0.03 1.1x10-10 
 
ESR1 6 152,397,912 rs36083386 I 0.11 323,303 0.439 0.05 1.5x10-18 G 
FNDC1 6 159,699,125 rs449789 C 0.14 325,584 0.359 0.05 2.4x10-15 GIU 
THBS2 6 169,587,103 rs1322639 A 0.78 319,866 0.316 0.04 4.8x10-17 G 
SUGCT 7 40,447,971 rs76206723 A 0.1 328,162 -0.346 0.05 7.4x10-12 GIU 
SLC20A2 8 42,324,765 rs2978456 T 0.55 304,964 -0.188 0.03 1.2x10-8 GIU 
TRAPPC9 8 141,060,027 rs4454254 A 0.63 330,022 -0.261 0.03 5.1x10-16 
 
SCAI 9 127,900,996 rs72765298 T 0.87 316,271 -0.374 0.05 2.7x10-14 GI 
KIAA1462 10 30,317,073 rs9337951 A 0.34 299,646 0.28 0.04 2.5x10-15 G 
ARHGAP12 10 32,082,658 rs10826995 T 0.71 327,373 -0.212 0.03 1.1x10-9 GIU 
PRDM11 11 45,208,141 rs11442819 I 0.11 326,483 -0.279 0.05 7.1x10-9 GIU 
NOX4 11 89,224,453 rs2289125 A 0.21 307,682 -0.377 0.04 9.1x10-22 G 
CEP164 11 117,283,676 rs8258 T 0.38 327,038 0.236 0.03 2.9x10-13 G 
CCDC41 12 94,880,742 rs139236208 A 0.1 291,244 -0.363 0.06 1.6x10-10 G 
RP11-61O1.1 14 98,587,630 rs9323988 T 0.63 327,551 -0.212 0.03 4.1x10-11 GIU 
VAC14 16 70,755,610 rs117006983 A 0.01 250,766 0.986 0.14 4.1x10-12 
 
CDH13 16 83,045,790 rs7500448 A 0.75 321,958 0.329 0.04 1.1x10-19 G 
KIAA0753 17 6,473,828 rs7226020 T 0.56 303,389 -0.256 0.03 2.3x10-14 GIU 
TP53-SLC2A4 17 7,571,752 rs78378222 T 0.99 294,053 0.904 0.14 1.8x10-10 GIU 
KCNH4-HSD17B1 17 40,317,241 rs79089478 T 0.97 318,326 0.584 0.1 3.1x10-9 
 
PYY 17 42,060,631 rs62080325 A 0.66 315,689 -0.186 0.03 4.0x10-8 
 
MRC2 17 60,767,151 rs740698 T 0.56 311,450 -0.228 0.03 3.1x10-12 
 
SLC14A2 18 43,097,750 rs7236548 A 0.18 330,075 0.352 0.04 2.0x10-18 G 
SLC24A3 20 19,465,907 rs6081613 A 0.28 315,546 0.263 0.04 1.6x10-13 GIU 
ARVCF 22 19,967,980 rs12628032 T 0.3 310,292 0.24 0.03 5.5x10-12 GIU 
XRCC6 22 42,038,786 rs73161324 T 0.05 267,722 0.496 0.07 2.8x10-11 
 
(b) Exome 
CD34 1 208,024,820 rs12731740 T 0.1 279,078 -0.249 0.04 1.1x10-8 
 
ZNF638 2 71,627,539 rs3771371 T 0.57 280,285 -0.16 0.03 5.8x10-9 GIU 
CRACR2B 11 828,916 rs7126805 A 0.73 145,162 0.222 0.04 3.3x10-9 
 
Locus: named according to nearest annotated gene(s); Chr: chromosome; Pos: build 37; EA: effect 54 
allele; EAF: EA frequency in UK Biobank; Beta: effect estimate; SE: Standard Error of effect; P: P-55 
value; N: total sample size analyzed; Note: indicates loci published since our analysis15 from GERA 56 
(G), GERA+ICBP(HapMap) (GI) or GERA+ICBP(HapMap)+UKB (GIU) analyses.57 
Online Methods 58 
UK Biobank data 59 
Our GWAS analysis is performed using data from the interim release of the first ~150k UK 60 
Biobank (UKB) participants (Supplementary Note): ~100k individuals from UK Biobank 61 
genotyped at ~800,000 single nucleotide variants (SNVs) with a custom Affymetrix UK Biobank 62 
Axiom Array chip and ~50k individuals genotyped with a custom Affymetrix UK BiLEVE Axiom 63 
Array chip from the UK BiLEVE study63, a subset of UKB. SNVs were imputed centrally by UKB 64 
using a merged UK10K sequencing + 1000G imputation reference panel. UK Biobank array 65 
design and protocols are available on the UK Biobank website. 66 
Quality control 67 
Following QC procedures already carried out centrally by UKB, we exclude discordant SNVs 68 
and samples with QC failures, gender discordance and high heterozygosity/missingness. We 69 
further restrict our data to a subset of individuals of European ancestry. By applying kmeans 70 
clustering to the Principal Component Analysis (PCA) data a total of N=145,315 Europeans 71 
remain (Supplementary Fig. 15). We use the kinship data to exclude 1st and 2nd degree 72 
relatives, with N=141,647 unrelated individuals remaining. Finally we restrict our data to non-73 
pregnant individuals with two automated BP measurements available, resulting in a 74 
maximum of N=140,886 individuals for analysis (Supplementary Note). 75 
Phenotypic data 76 
After calculating the mean SBP and DBP values from the two BP measurements, we adjust for 77 
medication use by adding 15 and 10 mmHg to SBP and DBP, respectively, for individuals 78 
reported to be taking BP-lowering medication (21.4% of individuals)64. PP is calculated as SBP 79 
minus DBP, according to the medication-adjusted traits. Hypertension, used in secondary 80 
analyses, is defined as: (i) SBP ≥ 140 mmHg, or (ii) DBP ≥ 90 mmHg, (iii) or taking BP-lowering 81 
medication; otherwise individuals are classified as non-hypertensive. Descriptive summary 82 
statistics are provided for all individuals (Supplementary Table 1).   83 
Statistical methods 84 
Statistical approaches used for the discovery and replication of loci are reported in detail 85 
below. We also describe methods used for: identification of secondary signals; lookups in non-86 
European populations and for monogenic BP genes; functional and experimental methods; 87 
construction of a genetic risk score for analysis with BP traits and cardiovascular outcomes. 88 
All P-values are from two-sided tests. 89 
Analysis models 90 
For the GWAS, we perform linear regression analyses of the three (untransformed) 91 
continuous, medication-adjusted BP traits (SBP, DBP, PP) for all measured and imputed 92 
genetic variants in dosage format using SNPTEST software65 under an additive genetic model. 93 
We carry out a similar analysis for the exome content. Quantile-quantile plots are shown in 94 
Supplementary Fig. 16. Each analysis includes the following covariates: sex, age, age2, body 95 
mass index, top ten PCs and a binary indicator variable for UK Biobank vs UK BiLEVE to adjust 96 
for the different genotyping chips. We also run an association analysis within UKB for 97 
validated BP SNVs and hypertension using logistic regression under an additive model with 98 
adjustments as above. There are 76,554 hypertensive cases and the 64,384 remaining 99 
participants are treated as non-hypertensive controls. This sample size is slightly larger than 100 
the N=140,866 used in the main analyses, since participants with only one BP measurement, 101 
but with reported BP-lowering medication, could be included as hypertensive. 102 
Previously reported variants 103 
We compile a list of all SNVs previously reported to be associated with BP at the time of 104 
analysis (Supplementary Table 13). This list includes all published SNVs which have been 105 
identified and validated from previous GWAS, CardioMetabochip and exome chip projects7-106 
11. We augment this list to include all 34,459 SNVs in Linkage Disequilibrium (LD) with these 107 
previously reported SNVs, according to a threshold of r2 ≥ 0.2. Results for all these variants 108 
are extracted for each of the three BP traits, to check previously reported BP associations in 109 
the UKB data, according to whether the sentinel SNV or a variant at the locus in LD (r2 ≥ 0.2) 110 
with it showed evidence of support (P < 0.01) for association with at least one of the three BP 111 
traits. 112 
Replication strategy 113 
We use three independent external data sets for replication (Supplementary Note). First, for 114 
the GWAS analysis based on advanced 1000G imputation enhanced by UK10K data we 115 
consider SNVs with MAF ≥ 1% and perform a reciprocal replication exchange with the 116 
International Consortium of Blood Pressure (ICBP) 1000G meta-analysis (max N = 150,134). 117 
The imputation strategy for ICBP 1000G meta-analysis is based on an earlier imputation grid 118 
for the 1000G project. In addition, we recruit further cohorts with 1000G data which had not 119 
contributed to the ICBP-1000G discovery meta-analysis: ASCOT-UK (N = 3,803), ASCOT-SC (N 120 
= 2,462), BRIGHT (N = 1,791), Generation Scotland (GS) (N = 9,749), EGCUT (N = 5,468), 121 
Lifelines (N = 13,292) and PREVEND (N = 3,619). This gives a total of N = 190,318 independent 122 
replication samples for the GWAS analysis. 123 
Second, because the UK Biobank and UK BiLEVE genotyping chips contain exome content, we 124 
sought replication from two BP exome consortia (European exome consortium and the 125 
Cohorts for Heart and Ageing research in Genome Epidemiology – CHARGE BP exome 126 
consortium), to allow validation of coding variants and variants with lower frequency. The 127 
European exome consortium (N = 161,926) and CHARGE consortium (N = 119,792) give a total 128 
of N = 281,718 independent replication samples for the exome analysis. 129 
 130 
Note that the lookups for GWAS and exome discovery are distinct sets of SNVs. Loci are 131 
assigned sequentially, prioritising the primary GWAS discovery first, then considering any 132 
remaining loci with non-overlapping exome content for replication in the independent exome 133 
replication resources. 134 
 135 
Statistical criteria for replication 136 
For the GWAS discovery, there are ~9.8 million SNVs with MAF ≥ 1% and INFO > 0.1. We 137 
consider for follow-up any SNVs with P < 1x10-6 for any of the three BP traits. For the exome 138 
discovery, there are 149,026 exome SNVs (Supplementary Note) which were polymorphic 139 
with INFO > 0.1; for follow-up we consider all SNVs with MAF ≥ 0.01% and P < 1x10-5. All such 140 
SNVs are annotated to loci according to both an LD threshold of r2 ≥ 0.2 and a 1Mb interval 141 
region (see Supplementary Note), and signals are classified either as belonging to unvalidated 142 
loci, or being potential secondary signals at previously reported loci at the time of analysis. 143 
Selection of variants for follow-up 144 
The sentinel (most significant) SNV from each association signal is selected for follow-up, all 145 
of which are pairwise-independent by LD (r2 < 0.2). For the GWAS discovery, we check that 146 
potential lookup SNVs are covered within the ICBP-1000G replication data (Supplementary 147 
Note; Supplementary Tables 28 and 29). Of the 235 novel loci containing previously 148 
unreported SNVs with MAF ≥ 1%, INFO > 0.1 and P<1x10-6, 218 are covered, and similarly 100 149 
of the 123 potential secondary SNVs at 51 of the 54 previously reported BP loci are available 150 
for follow-up. For the exome discovery, by following up SNVs with MAF ≥ 0.01%, INFO > 0.1 151 
and P < 1x10-5 across the three BP traits, we carry forward for replication sentinel SNVs at 22 152 
unvalidated loci, and potential secondary SNVs at three previously reported loci at the time 153 
of analysis. We produce locus zoom plots for each of the lookup variants.  154 
Replication meta-analyses 155 
The replication and combined meta-analyses are performed within METAL software66 using 156 
fixed effects inverse variance weighted meta-analysis (Supplementary Note). The combined 157 
meta-analysis of both the UKB discovery (N = 140,886) and GWAS replication meta-analysis 158 
(max N = 190,070) include a total maximum sample size of N = 330,956. For the exome 159 
combined meta-analysis, we synthesize data from the UKB discovery exome content (max 160 
N=140,866), with the replication dataset from both exome consortia (total max N=281,718), 161 
giving a maximum sample size of N=422,604. 162 
Validation Criteria 163 
In our study a signal is declared validated if it satisfies ALL of the following three criteria:  164 
(i) the sentinel SNV is genome-wide significant (P < 5×10-8) in the combined meta-165 
analysis for any of the three BP traits;  166 
(ii) the sentinel SNV shows evidence of support (P < 0.01) in the replication meta-167 
analysis alone for association with the most significantly associated BP trait from 168 
the combined meta-analysis (NB: P < 0.01 is more stringent than a range of 169 
thresholds calculated according to False Discovery Rate (FDR), see Supplementary 170 
Methods); 171 
(iii) the sentinel SNV has concordant direction of effect between the UKB discovery 172 
and the replication meta-analysis for the most significantly associated BP trait 173 
from the combined meta-analysis. 174 
Secondary signals  175 
By conditional analysis within UKB data we assess all validated secondary signals from our 176 
validated and previously reported loci at the time of analysis for independence from the 177 
sentinel or previously reported SNV, respectively (Supplementary Note). We declare a 178 
secondary signal to be independent of the previously reported SNV if there is less than a 1.5 179 
fold difference between the main association and conditional association P-values on a –log10 180 
scale, i.e. if –log10(P) / -log10(P_cond) < 1.5. Note that the lookup criteria already ensure that 181 
the secondary variant is not in LD (r2 < 0.2) with the previously reported SNV. If more than 182 
one SNV in a region is found to be independent we undertake further rounds of iterative 183 
conditional analysis.  184 
Lookups in non-European ancestries 185 
As a secondary analysis, we look up 102 and 5 validated SNVs from the GWAS and exome 186 
analyses, respectively, in non-European ancestry samples. These comprise analysis of East 187 
Asian (N = 31,513) and South Asian (N = 33,115) ancestry data from the iGEN-BP consortium11 188 
for the GWAS lookups, and South Asian (N = 25,937), African American (N = 21,488) and 189 
Hispanic (N = 4,581) ancestry data from the CHARGE BP exome consortium10 and CHD+ Exome 190 
consortium9, for the exome content lookups (Supplementary Note). We carry out a binomial 191 
(sign) test based on the number of SNVs with consistent directions of effect between UKB and 192 
each of the non-European ancestry samples. 193 
Monogenic blood pressure gene lookups  194 
The UKB arrays include some rare coding variants for monogenic disorders. We collate a list 195 
of all specific mutation variants within genes known to be associated with monogenic BP 196 
disorders19. Results from the UKB association analyses for all three BP traits are extracted for 197 
any of these SNVs directly covered within the UKB dataset (Supplementary Table 14). Note 198 
that a search of proxies did not augment the list of available variants, so results are reported 199 
for the specific variants only. 200 
Functional analyses 201 
In order to prioritize associated SNVs, we use an integrative bioinformatics approach to 202 
collate functional annotation (Supplementary Table 30) at both the variant and gene level for 203 
each SNV within the BP loci (all SNVs in LD r2 ≥ 0.8 with the BP-associated SNVs). At the variant 204 
level we use ANNOVAR67 to obtain comprehensive functional characterization of variants, 205 
including gene location, conservation and amino acid substitution impact based on a range of 206 
prediction tools including SIFT and polyphen2. All nonsynonymous variants were predicted 207 
damaging by two or more methods.  208 
We use the University of California Santa Cruz (UCSC) genome browser to review sequence 209 
specific context of SNVs in relation to function, particularly in the Encyclopedia of DNA 210 
Elements (ENCODE) dataset68. We use the UCSC table browser to annotate SNVs in ENCODE 211 
regulatory regions.  We evaluate SNVs for impact on putative micro RNA target sites in the 3’ 212 
un-translated regions (3’UTR) of transcripts by a query of the miRNASNP database69. We 213 
evaluate all SNVs in LD (r2 ≥ 0.8) with our validated sentinel SNVs for evidence of mediation 214 
of expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-Tissue 215 
Expression (GTEx) database, in order to identify validated loci which are highly expressed, and 216 
to highlight specific tissue types which show eQTLs for a large proportion of validated loci. 217 
We further seek to identify validated loci with the strongest evidence of eQTL associations in 218 
arterial tissue, in particular. 219 
At the gene level, we use Ingenuity Pathway Analysis (IPA) software (IPA®,QIAGEN Redwood 220 
City) to review genes with prior links to BP, based on annotation with the “Blood Pressure” 221 
Medline Subject Heading (MESH) term which is annotated to 684 genes. We also use IPA to 222 
identify genes which interact with BP MESH annotated genes, and evaluate genes for 223 
evidence of small molecule druggability based on queries of Chembl and Drug Gene 224 
Interaction database. 225 
We then perform overall enrichment testing across all loci. Firstly, we use DEPICT70 (Data-226 
driven Expression Prioritized Integration for Complex Traits) to identify highly expressed 227 
tissues and cells within the BP loci. DEPICT uses a large number of microarrays (~37k) to 228 
identify cells and tissues where the genes are highly expressed and uses precomputed GWAS 229 
phenotypes to adjust for co-founding sources. DEPICT provides a P-value of enrichment and 230 
false discovery rates adjusted P-values for each tissue/cells tested.  231 
Furthermore, to investigate regulatory regions, we employ a two tiered approach to 232 
investigate cell type specific enrichment within DNase I sites using FORGE, which tests for 233 
enrichment of SNVs within DNase I sites in 123 cell types from the Epigenomics Roadmap 234 
Project and ENCODE71 (Supplementary Note). Validated sentinel SNVs from our study are 235 
analysed along with previously reported SNVs at the time of analysis and secondary signals 236 
(with P-value < 1×10-4) to evaluate the overall tissue specific enrichment of BP associated 237 
variants.  In a second analysis we use FORGE (with no LD filter) to investigate directly our 238 
curated candidate regulatory SNVs for overlap with cell-specific DNase I signals. 239 
GenomeRunner72 is used to search for enrichment of validated and previously reported 240 
sentinel SNVs with histone modification mark genomic features (Supplementary Note). 241 
Relevant cardiovascular tissue expression is investigated using Fantom5 reference transcript 242 
expression data (fantom.gsc.riken.jp/5) (Supplementary Note).   243 
We use IPA (IPA®,QIAGEN Redwood City) to identify biological pathways and transcriptional 244 
upstream regulators enriched for genes within the BP loci. The transcriptional upstream 245 
regulator analysis aims to identify transcription factors, compounds, drugs, kinases and other 246 
molecules, for which the target is one of the BP genes under investigation.  247 
We query SNVs against PhenoScanner16 to investigate trait pleiotropy, extracting all 248 
association results with nominal significance at P < 0.05 for full reporting (Supplementary 249 
Table 16), and then extract genome-wide significant results to highlight the validated loci with 250 
strongest evidence of association with other traits (Supplementary Fig. 5a). We also use the 251 
Genomic Regions Enrichment of Annotations Tool (GREAT) to study gene set enrichment of 252 
mouse phenotype and disease ontology terms within our validated and previously reported 253 
loci at the time of analysis, using default SNV to gene mapping settings73.    254 
We carry out metabolomics analysis using two sets of data. First we use 1H NMR lipidomics 255 
data on plasma from a subset of 2,000 participants of the Airwave Health Monitoring 256 
Study74,75 (Supplementary Note). For each validated BP-associated SNV we ran association 257 
tests with the lipidomics data using linear regression analyses, adjusted for age and sex. We 258 
computed significance thresholds using a permutation derived family wise error rate (5%) to 259 
account for the high correlation structure of these data (ENT=35)76. We also test each 260 
validated SNV against published genome-wide vs metabolome-wide associations in plasma 261 
and urine using publicly available data from the “Metabolomics GWAS Server” to identify 262 
metabolites that have been associated with variants of interest at P < 3.0 x 10-4 (Bonferroni 263 
corrected P for validated signals)22,23. 264 
Experimental methods 265 
We prioritize genes for laboratory testing on the basis of evidence for SNV function (including 266 
coding variants, eQTLs and Hi-C interactions), biological support for relevance to BP (from 267 
literature review) and transgenic phenotype. We perform genotyping and Quantitative 268 
Reverse-Transcription Polymerase Chain Reaction (q RT-PCR) for the selected sentinel 269 
variants of interest using human vascular smooth muscle cells and endothelial cells and test 270 
for expression levels (Supplementary Note; Supplementary Table 31). All three SNVs were 271 
tested using an additive model. 272 
Genetic risk scores  273 
Genetic risk scores (GRS) are constructed using the independent Airwave study74 data to 274 
assess the combined effect of the BP-associated variants on BP and risk of hypertension 275 
(Supplementary Note), whilst avoiding bias by “winners curse”. We create weighted GRSs for 276 
all pairwise-independent, LD-filtered (r2 < 0.2) previously reported variants at the time of 277 
analysis and our validated variants (sentinel and secondary SNVs) combined, using available 278 
SNVs (Supplementary Table 22). For the previously reported variants, we weight BP 279 
increasing alleles by the beta coefficients from the UKB analysis. For our validated variants, 280 
beta coefficients of the replication meta-analysis are used as independent, unbiased weights.  281 
For the variance explained analyses within the independent Airwave cohort, we use three 282 
trait-specific GRSs (SBP, DBP, PP). Each GRS includes all variants, but weights are trait-specific, 283 
using the beta coefficients from the analysis of each of the three different BP traits, e.g. the 284 
SBP-GRS is weighted by the beta coefficients from the SBP-GWAS. To calculate the percent of 285 
variance for each BP trait explained by its corresponding trait-specific GRS, not accounted for 286 
by known factors, we generate the residuals from the regression model of each trait against 287 
covariates of age, age2, sex and body mass index. We then fit a second linear model for the 288 
trait residuals with all the variants in the GRS plus the top 10 PCs. 289 
For risk score analyses we calculate a single BP GRS, as the average of the SBP and DBP GRSs. 290 
We standardize the average GRS to have mean of zero and standard deviation of one. We 291 
assess the association of the continuous average GRS variable with each BP trait by simple 292 
linear regression. We also run a logistic regression to examine the association of the average 293 
GRS with risk of hypertension. We perform each analysis both with and without adjustment 294 
for sex. We test for interaction between age (< 50, and ≥50 years) and the effect of the GRS 295 
on BP. We then compare BP levels and risk of hypertension for individuals in the top and 296 
bottom 20% of the GRS distribution at ≥50 years using linear and logistic regression, 297 
respectively. 298 
We also assess the association of the average BP GRS with cardiovascular outcomes in the 299 
UKB data. We include all pairwise-independent previously reported BP variants at the time of 300 
analysis, and our validated variants. We use logistic regression with binary outcome variables 301 
for coronary heart disease, stroke and cardiovascular disease (see Supplementary Note) and 302 
GRS as explanatory variable (with and without sex adjustment).  303 
 304 
 305 
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